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Background: Exposure to anthracyclines (ANT) during childhood represents a high risk for development of late
cardiotoxicity. Cardiotoxicity is usually detected only when clinical symptoms or progressive cardiac dysfunction
have already occurred. Early detection of cardiotoxicity may lead to better therapeutic outcome. N-terminal pro-
brain natriuretic peptide (NTproBNP) has been hypothesized to reflect increased left ventricular wall stress before
development of echocardiographic abnormalities. The aim of this study was to detect cardiac abnormalities using
plasma NTproBNP and echocardiography in asymptomatic childhood leukemia survivors treated with or without
cardiotoxic anthracycline therapy.
Methods: Serum levels of NTproBNP were determined in 69 asymptomatic survivors of childhood leukemia treated
with or without anthracyclines and in 44 apparently healthy controls. The survivors were divided into two
treatment groups: 36 patients after chemotherapy containing anthracyclines (ANT) and 33 patients after
chemotherapy without anthracyclines (nonANT). Levels of NTproBNP were measured by using the Elecsys 2010
immunoassay analyzer (Roche Diagnostics). Echocardiography using M-mode, two-dimensional and Doppler
measurements were performed on the same day as blood samples were obtained for NTproBNP analysis
in survivors.
Results: Serum levels of NTproBNP were significantly higher in the ANT group than in controls (median 51.52 vs
17.37 pg/ml; p=0.0026). Survivors exposed to ANT had significantly increased levels of NTproBNP compared with
patients treated without ANT (median 51.52 vs 12.24 pg/ml; p=0.0002). Female exposed and unexposed survivors
had significantly higher NTproBNP levels than males. Four of the 36 survivors (11%) treated with ANT and two of
the 33 patients (6%) not exposed to ANT had abnormal NTproBNP levels. Although no patient had
echocardiographic abnormalities, significant differences were found in values of left ventricular ejection fraction
(LVEF) and deceleration time (DT) between survivors treated with or without anthracyclines.
Conclusions: Higher levels of NTproBNP detected in childhood leukemia survivors after low anthracycline
cumulative doses might reflect an initial stage of ANT cardiotoxicity before the development of echocardiographic
abnormalities. Although the current studies support NTproBNP as one of the best available biochemical markers of
late anthracycline cardiotoxicity, a possible strategy toward further improvement and combination with other
cardiac biomarkers and novel echocardiographic methods should be explored in additional studies.
Keywords: Cardiotoxicity, Anthracyclines, Natriuretic peptides, Echocardiography, Survivors* Correspondence: beata.mladosievicova@fmed.uniba.sk
1Institute of Pathological Physiology, School of Medicine, Comenius
University, Sasinkova 4, 811 08, Bratislava, Slovak Republic
Full list of author information is available at the end of the article
© 2012 Mladosievicova et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.








Sex M/F 19/17 16/17 22/22
Diagnosis ALL (33) ALL (33)
(No. of pts) AML (3)





11 (5–22) 15 (6–25)
Age at time of the
study, yrs







Values are presented as median (range).
ALL, acute lymphoblastic leukemia; AML, acute myeloblastic leukemia.
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Childhood cancer survivors exposed to anthracyclines
are at increased risk for premature cardiac morbidity
and mortality [1-8]. For 30 years after cancer treatment,
survivors are 15 times more likely to experience heart
failure than the general population [8]. Cardiac effects of
the therapy for acute leukemia in childhood are of par-
ticular concern. In more than half of the exposed survi-
vors, cardiotoxic treatment was found to be associated
with left ventricular (LV) subclinical structural and func-
tional abnormalities, which can progress to clinically
manifested heart failure [9].
Diagnosis of cardiac dysfunction and heart failure after
anticancer therapy is based on medical history, physical
examination and is further confirmed by other tests,
mainly echocardiography. Nevertheless, clinical misdiag-
nosis is common, particularly in early stages of heart
failure. Current monitoring techniques, such as MUGA
(Multi Gated Acquisition Scan) or echocardiography,
have substantial limitations and detect LV dysfunction
only after it had occurred. Cardiotoxicity is usually diag-
nosed only upon manifestation of clinical signs and
symptoms or progressive cardiac dysfunction. Thus new
diagnostic tests are required to confirm ventricular dys-
function induced by anticancer therapy .
Novel echocardiographic techniques are promising in
evaluating the presence of myocardial structural altera-
tions and subtle myocardial dysfunction induced by
anticancer therapy, yet they are not used in routine clin-
ical practice.
Although new cardiac imaging techniques, such as quanti-
tative assessment of ventricular function through measure-
ment of myocardial strain and strain rate can more precisely
assess heart structure and function during and early after
cardiotoxic therapy, it remains to be proven whether they
have the ability to detect early treatment-induced cardiac in-
jury in long-term cancer survivors several years after com-
pletion of malignancy therapy. Morevover, the definition of
reference range of ventricular strain and strain rate values in
normal adults and description of the variability among sys-
tems and observers are debatable [10,11].
Early and accurate diagnosis of ventricular dysfunction
in asymptomatic cardiac patients may permit a prompt
onset of therapy of subclinical cardiotoxicity before the
development of life-threatening complications.
This study aims to detect cardiac abnormalities
using plasma N-terminal pro brain natriuretic peptide
(NTproBNP) and echocardiography in asymptomatic
childhood leukemia survivors treated with or without
cardiotoxic anthracyclines (ANT).
Methods
Childhood acute leukemia survivors without any cardiac
symptoms were consecutively recruited in the out-patient clinic of the National Cancer Institute, Bratislava,
Slovak Republic, from January 2006 to October 2010. A
total of 69 survivors of acute leukemia were involved,
aged 17–31 years, whose chemotherapy completion
dated back for at least 5 years. They had been treated
between 1985 and 2005 in a single center – at the Chil-
dren´s University Hospital, Bratislava. Survivors were
divided into two treatment groups: 36 patients who had
received chemotherapy containing cardiotoxic anthracy-
clines (ANT) and 33 patients after chemotherapy with-
out anthracyclines (nonANT) (Table 1). Only one
patient was treated with ANT in combination with me-
diastinal radiation.
The survivors who had received the cardioprotective
agent dexrazoxane were excluded. Furthermore, patients
with renal insufficiency, liver dysfunction, abnormal
blood pressure, abnormal body mass index and those
who were on any current medication, were excluded to
avoid possible effects on NTproBNP values.
To establish NTproBNP reference values, we selected
a control group of 44 subjects (aged 20–28 years, 50%
women) without any known cardiovascular risk factors
and no clinical evidence of heart, lung, renal, liver or
systemic disease. A blood sample was drawn and stored
under the same conditions as in the patients. In this
study, our normal values of NTproBNP were different
for females (<105 pg/mL) and males (<75 pg/mL) (below
97.5th percentile from controls).
All participants or their guardians gave their written
informed consent. The study was approved by the Ethics
Committee of the National Cancer Institute and the
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All patients were examined by a general cardiologist.
The blood samples for immunochemical analysis were
obtained at the same day as the echocardiographic
measurement was performed.
Biochemical analysis
EDTA-anticoagulated blood (5 ml) was collected by ven-
ous puncture. Fasting was not a prerequisite before sam-
pling. The whole blood was centrifuged for 10 minutes
(3500 rpm) within 2 h after sampling. Centrifuged
plasma (500 μL) was aliquoted to labeled eppendorf
tubes before freezing and stored at −20°C until assayed.
The cardiac biomarker NTproBNP was measured at
the Clinical Biochemistry Department, National Cardio-
vascular Institute, Bratislava, Slovak Republic, within
two months after collection. Hemolyzed samples were
excluded. Venous blood samples were obtained in the
morning and serum concentrations of biomarkers were
measured by electrochemiluminescence immunoassay
on Elecsys analyzer (Roche Diagnostics). The detection
limit for the NTproBNP assay is 5 pg/mL.
We compared the NTproBNP levels between the stud-
ied groups exposed and unexposed to ANT and our age-
and sex-matched control group.
Echocardiography
Echocardiography using a GE VIVID 7 machine (GE
Ultrasound Europe) was performed in all patients
included in the study. Assessment was done by one
experienced cardiologist who was unaware of the partici-
pants’ treatment status and the NTproBNP value.
Standard techniques were used to obtain M-mode,
two-dimensional and Doppler (color, pulse, continuous,
tissue) echocardiograms.
Left ventricular (LV) end-diastolic diameter (LVEDD),
LV end-systolic diameter (LVESD) and left atrium di-
mension were measured using standard M-mode meth-
ods from parasternal LV long axis images. LV ejection
fraction (EF) was calculated by Teichholz formula (M-
mode) as well as by the Simpson method from apical
view (two-dimensional echocardiography). Systolic LV
dysfunction was defined as EF less than or equal to 50%.
Quantification of metric and functional echocardio-
graphic parameters was based on the recommendations
of the American Society of Echocardiography´s Guide-
lines and Standards Committee and the Chamber Quan-
tification Writing Group [12].
Pulsed Doppler traces of the mitral valve inflow were
used to extract the ratio of peak early to peak late flow
velocities (E/A), E-wave deceleration time (DT), LV iso-
volumetric relaxation time (IVRT) and were assessed as
standard parameters of LV diastolic function. DiastolicLV dysfunction was defined as E/A inversion and DT
above 220 ms on the transmitral Doppler curve
(impaired relaxation).
The tissue Doppler imaging (TDI) of the mitral annu-
lus from apical four-chamber view provided additional
parameters reflecting the global systolic and diastolic
function of the LV. Early diastolic velocity (Ea) of the
mitral annulus was considered a good indicator of LV
myocardial relaxation and diastolic function, and so was
the ratio of early diastolic myocardial velocity (Em) and
late diastolic myocardial velocity (Am).
Peak systolic velocity at myocardial segments (Sm)
was used to assess systolic function. The ratio of early
diastolic LV inflow velocity (E) to Ea of the medial mitral
annulus (E/Ea) was used for estimation of the LV filling
pressure [13].Statistical analysis
Continuous variables (echocardiographic parameters)
are presented as mean ± SD (standard deviation) and
the cardiac biomarker NTproBNP as median and inter-
quartile range. Comparisons between continuous or cat-
egorical variables were performed using the Student
t-test, Mann–Whitney and Wilcoxon test. Correlations
were evaluated with Spearman correlation coefficient. A
p-value less than 0.05 was considered statistically
significant.Results
Serum levels of NTproBNP were significantly higher in
survivors treated with anthracylines than in controls
(median 51.52 vs 17.37 pg/mL; p=0.0026). Survivors
exposed to ANT had significantly increased levels of
NTproBNP compared with survivors treated without
ANT (median 51.52 vs 12.24 pg/mL; p=0.0002). Levels
of NTproBNP in survivors not exposed to ANT com-
pared with controls were not significantly different (me-
dian 12.24 vs 17.37 pg/mL; p=0.051) (Figure 1).
Abnormal NTproBNP levels were detected in 4/36
(11%) survivors in the ANT group and in 2/33 (6%) in
the nonANT group.
Women exposed to anthracyclines had significant-
ly higher values of NTproBNP than exposed men: me-
dian (25th-75th percentiles): 82.6 (51.5-99.1) vs 38.1
(22.2-53.7) pg/mL; p = 0.0031.
Unexposed female survivors had significantly higher
values of NTproBNP than unexposed male survivors:
median (25th-75th percentiles): 44.6 (21.6-83.2) vs 17.6
(12.5-24.7) pg/mL; p= 0.0039 (Table 2).
No significant differences in NTproBNP values were
found between females and males from control group:
median (25th-75th percentiles): 28.8 (17.1-44.5) vs 17.2

















Figure 1 Comparison of serum levels of NTproBNP in studied
groups. Box plot shows the minimum, maximum, interquartile
range (box), and median values for survivors previously treated with
and without ANT and for apparently healthy controls. Whiskers
above and below boxes indicate the 90th and 10th percentiles.
Closed circles outside of boxes indicate outliers.
Table 3 Echocardiographic parameters in the groups of
survivors
NonANT group ANTgroup P value
LVEF (%) (Simpson) 69.8 ± 6.4 66.4 ± 4.5 < 0.05
Sm 0.12 ± 0.03 0.16 ± 0.16 NS
E/A 1.8 ± 0.5 1.7 ± 0.5 NS
DT (ms) 195.3 ± 32.9 219.6 ± 55.5 < 0.05
IVRT (ms) 72.2 ± 7.9 74.1 ± 7.9 NS
E/Ea 6.5 ± 1.4 6.2 ± 1.6 NS
Em/Am 2.3 ± 0.7 2.1 ± 0.6 NS
LVEDD (mm) 45.7 ± 4.9 46.2 ± 4.2 NS
LVESD (mm) 28.1 ± 6.4 29.3 ± 3.5 NS
LA (mm) 32.4 ± 3.9 32.5 ± 4.2 NS
RV (mm) 26.1 ± 3.2 26.1 ± 3.4 NS
Values are presented as mean ± SD.
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ities, significant differences were found in values of left
ventricular ejection fraction (LVEF) and deceleration
time (DT) between survivors exposed and not exposed
to anthracyclines (Table 3).
NT proBNP values positively correlated with ANT
dose (rho = 0.51, p = 0.0028) but failed to correlate with
LVEF (rho = 0.1488, p= 0.4245) and DT (rho = 0.1506, p
= 0.4269).
Discussion
Measurement of natriuretic peptides (NP) is routinely
used in diagnosis and management of cardiac dysfunc-
tion and heart failure [14]. Natriuretic peptides are pro-
duced within the heart and released into the circulation
in response to increased wall tension, reflecting
increased volume or pressure overload. Under patho-




Median (25th-75th) 82.6 (51.5-99.1) 38.1 (22.2-53.7) 0.0031
Unexposed N=17 N=16
Median (25th-75th) 44.6 (21.6-83.2) 17.6 (12.5-24.7) 0.0039
Controls N=22 N=22
Median (25th-75th) 28.8 (17.1-44.5) 17.2 (10.3-33.9) 0.12
NTproBNP, N-terminal pro-brain natriuretic peptide. Results are expressed as
median and quartiles.cleaved to BNP, releasing N-terminal fragment of the
brain natriuretic peptide (NTproBNP). Many studies
reported that NTproBNP concentrations increased with
the severity of ventricular dysfunction and heart failure
[13,15,16,17].
NTproBNP is a promising candidate marker for the
exclusion and detection of ventricular dysfunction after
potentially cardiotoxic anticancer therapy [2,13,15-28].
Although the role of NTproBNP in the early detection
of myocardial damage after anticancer therapy has been
evaluated in several studies, the focus was mainly on
levels of this biomarker during or only several months
after chemotherapy [13,18-20,22,23]. So far only a lim-
ited number of studies have investigated the levels of
NTproBNP as a marker of late cardiotoxicity occurring
several years after completion of chemotherapy in can-
cer survivors [2,26-28]. In our recent study, we have
found significantly elevated NTproBNP levels in child-
hood leukemia survivors at a median of 10.5 years after
completion of anthracycline therapy in comparison with
apparently healthy controls [27].
In the present study, this finding was extended to
show NTproBNP levels not only in survivors after ANT
therapy but also in patients unexposed to anthracyclines.
The NTproBNP values in unexposed survivors were
found to be comparable to those determined in the con-
trol group. According to our information, only one other
study reported recently NTproBNP levels in survivors
who received ANT compared with patients not receiving
these agents [28]. These authors confirmed higher
NTproBNP values in the ANT group than in controls
yet they found that not only exposed but also unexposed
survivors had elevated NTproBNP. They suggest that a
chronic inflammatory process may be a predisposing fac-
tor of cardiomyopathy in cancer survivors unexposed to
anthracyclines. Systemic inflammation in cancer
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physiological studies. The discrepancy between the study
of Lipshultz et al. [28] and the presented study might be
explained by differences in characteristics of the study
participants (cancer treatment history, gender, age, body
mass index and other risk factors).
In the present study, the detection of cardiotoxicity
was performed in childhood leukemia survivors after a
low cumulative ANT dose (with median 221 mg/m2). So
far only few studies have been published that assessed
cardiotoxicity after such ANT doses [26,27]. We found
significantly higher serum levels of NTproBNP in
patients exposed to anthracyclines than in unexposed
survivors and controls. These results might reflect
anthracycline-induced cardiac abnormalities (such as
loss of cardiomyocytes and damage of the remaining car-
diomyocytes and other myocardial cells).
The sex-related differences in NTproBNP levels
in our patients are consistent with other authors
demonstrating that female survivors are more vulner-
able to anticancer cardiotoxic and non- cardiotoxic
treatments [28].
In the study we found that 11% survivors treated with
ANT (with median cumulative dose 221 mg/m2) and 6%
of patients previously unexposed to anthracyclines had
abnormal NTproBNP levels. In the study of
Mavinkurve-Groothius et al. [26], abnormal levels of
NTproBNP were detected in 13% of 122 asymptomatic
survivors of childhood cancer who had received a
median cumulative ANT dose comparable to our study.
These authors used published reference values for
adults derived from a population older or equal to
50 years [29]. The applicability of these cut-off reference
NTproBNP values to our adolescent and young
adult population may be debatable. In the present study,
normal values of NTproBNP were different for females
(<105 pg/mL) and males (<75 pg/mL) (below 97.5th per-
centile from our controls).
Similarly as in some studies, NTproBNP levels were
significantly related to cumulative ANT dose in our sur-
vivors, yet these concentrations were not correlated with
LVEF and DT [23,26].
Given the young age of our survivor population and
the rarity of other diseases in young patients, the
increased values of NTproBNP found in survivors may
provide an useful information on late ANT subclinical
cardiotoxicity.
Conclusions
Higher levels of NTproBNP detected in childhood
leukemia survivors after low anthracycline cumulative
doses might reflect an initial stage of ANT cardiotoxi-
city before the development of echocardiographic abnor-
malities. Although the current studies supportNTproBNP as one of the best available biochemical mar-
kers of late anthracycline cardiotoxicity, a possible strat-
egy toward further improvement and combination with
other cardiac biomarkers and novel echocardiographic
methods should be explored in additional studies.
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